NewAmsterdam Pharma Company N.V.
NASDAQ · us_market
No AI insight generated yet for this ticker.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 8.77M | $280.59M | 0.01% | Added+36.7% | 2026-03-31 |
| Wellington | fundamental | 5.12M | $163.76M | 0.03% | Added+1.6% | 2026-03-31 |
| Viking | long/short | 4.20M | $134.56M | 0.38% | Unchanged | 2026-03-31 |
| StateStreet | passive | 63.1K | $2.02M | 0.00% | Trimmed-7.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -0.42 | — | — |
| 2026-05-07 | -0.41 | -0.34 | +16.94% |
| 2026-02-18 | -0.37 | -0.53 | -45.31% |
| 2025-11-05 | -0.34 | -0.53 | -54.04% |
| 2025-08-06 | -0.43 | -0.13 | +69.85% |
| 2025-05-08 | -0.44 | -0.30 | +30.90% |
| 2025-02-26 | -0.47 | -0.90 | -94.02% |
| 2024-11-06 | -0.45 | -0.16 | +63.30% |
| 2024-08-07 | -0.52 | -0.38 | +28.19% |
| 2024-05-08 | -0.48 | -0.99 | -107.43% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NAMS | +18.47% | +10.77% | -3.99% | +85.97% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +15.50% | +15.41% | -0.55% | +73.29% |